Advertisement


Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

2025 ASCO Annual Meeting

Advertisement

Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
In this work, we did an individual patient data meta-analysis of trials looking at docetaxel with ADT (androgen deprivation therapy) and radiotherapy for high-risk localized prostate cancer. Now, we know as a way of background that radiotherapy plus long-term ADT for about two years is a standard of care for the treatment of men with high-risk localized prostate cancer. More recently, the addition of abiraterone has improved outcomes even further in men with very high-risk disease in the STAMPEDE trial. Now, docetaxel is a chemotherapy drug that has proven benefit in metastatic and advanced prostate cancer. It has been looked at in a series of trials in the localized setting, but mixed results have been seen. So what we set out to do here was to collate the data available within the ICECaP repository of trials looking at docetaxel and perform the individual patient data meta-analysis. Specifically, we wanted to see whether men with very high-risk disease—so we've actually done prior work from ICECaP showing that within high-risk prostate cancer, patients with two to three high-risk factors—so Gleason 8 or above, PSA greater than 20, clinical T3 or T4 disease, and/or clinical node-positive disease—these are the patients that do poorest with radiotherapy and long-term ADT. So we wanted to see (A) is docetaxel doing anything overall, and (B) specifically, is it beneficial in the very high-risk patients. So what did we do? We had four randomized trials available within the ICECaP repository, and we classified patients as either high-risk disease with one risk factor or very high-risk disease with two to three. And we primarily looked at the following five outcomes: MFS (metastasis-free survival), OS (overall survival), EFS (event-free survival), prostate cancer death, and time to metastasis. Overall, there were around 1,700 patients included—around 650 had high-risk disease (so one high-risk factor), and the remainder, around 1,000, had two to three high-risk factors (very high-risk disease). In the overall population—so all 1,700 patients—there was not a significant benefit to the addition of docetaxel to radiotherapy and ADT for high-risk localized disease. In terms of metastasis-free or overall survival, the hazard ratios were less than one, but it was not significant—the boundary crossed one. In very high-risk patients compared to high-risk patients, there did appear to be a greater benefit for adding docetaxel. So the hazard ratios in the high-risk population for MFS, OS, and other endpoints were in the 0.9 range, and for the very high-risk patients, they were in the 0.7–0.8 range, suggesting a greater benefit or a potential greater benefit for docetaxel in the very high-risk patients. Now, this was not statistically significant in terms of an interaction significance, but clinically there does appear to be a greater benefit, maybe in these very high-risk patients. So where do we take this forward? Well, right now standard of care for patients is ADT for two years, radiotherapy, and maybe abiraterone or another androgen pathway inhibitor. Now, could we do some biomarker work in the very high-risk patients to find out who might stand to benefit most from something like docetaxel? And can we then use that to design a trial to evaluate intensification beyond just ADT plus radiotherapy—maybe even an ARPI and adding docetaxel? I think that's where we would look to take this next. Docetaxel is a cheap drug. It's very widely used. It's easily available. So this would be a natural extension to this work.

Related Videos

Lung Cancer

David R. Spigel, MD, FASCO, on NSCLC Treatment Planning: Role of 14-Gene Molecular Assay

David R. Spigel, MD, FASCO, Chief Scientific Officer of Sarah Cannon Research Institute, reviews data on the role of a 14-gene molecular assay in selecting patients with stage IA–IIA non–small cell lung cancer (NSCLC) as high risk (LBA8027). 

Leukemia

Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025

Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual Meeting. 

Asaf Maoz, MD, on Li-Fraumeni Syndrome: Multimodality Screening Program 

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, reviews the results of a prospective study of whole-body magnetic resonance imaging as part of cancer screening for individuals with Li-Fraumeni syndrome (Abstract 10501). 

Lung Cancer

Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, offers his thoughts on findings from the primary analysis of the phase III DeLLphi-304 trial, which compared tarlatamab-dlle, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, with chemotherapy as a second-line treatment of patients with small cell lung cancer (SCLC) (LBA8008). 

Breast Cancer
Issues in Oncology

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do GLP-1 receptor agonists (GLP-1 RAs), a class of weight-loss medications, have cancer risk reduction properties (Abstracts 10507 and 10508). 

Advertisement

Advertisement




Advertisement